Attenuation of KATP channel-opener induced shortening of repolarization time by alpha 1-adrenoceptor antagonist during ischemia in canine heart.

abstract：:To further evaluate the significance of p38 MAPK as trigger or mediator in ischaemic preconditioning, anisomycin and SB 203580 were used to manipulate its activation status. Special attention was given to the concentration of the drugs and protocols used. The isolated perfused rat heart, subjected to either 25 min glo...

journal_title：Cardiovascular drugs and therapy

authors： Lochner A,Genade S,Hattingh S,Marais E,Huisamen B,Moolman JA

更新日期：2003-05-01 00:00:00

abstract：BACKGROUND:Recent studies in rabbits have demonstrated that platelet P2Y12 receptor antagonists are cardioprotective, and that the mechanism is surprisingly not related to blockade of platelet aggregation but rather to triggering of the same signal transduction pathway seen in pre- and postconditioning. We wanted to de...

journal_title：Cardiovascular drugs and therapy

authors： Yang XM,Liu Y,Cui L,Yang X,Liu Y,Tandon N,Kambayashi J,Downey JM,Cohen MV

更新日期：2013-04-01 00:00:00

abstract：:Recent surveys in the U.S. have reported, for the first time, that a significant number of patients with hypertension are finding that the cost of medication and treatment in general is an obstacle to treatment. The cost of management of hypertension can be contained if: a) the diagnostic workup is kept simple (this d...

journal_title：Cardiovascular drugs and therapy

authors： Moser M

更新日期：1989-10-01 00:00:00

abstract：:The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction o...

journal_title：Cardiovascular drugs and therapy

authors： Zanchetti A

更新日期：1995-08-01 00:00:00

abstract：:Milrinone is shown in 10 patients to be a valuable pharmacological bridge to heart transplantation; it can stabilize and improve decompensated chronic heart failure (CHF) in cases where the response to beta-agonists is inadequate. One patient who had suffered an acute myocardial infarction with heart failure resistant...

journal_title：Cardiovascular drugs and therapy

authors： Sherry KM,Locke TJ

更新日期：1993-08-01 00:00:00

abstract：:There is still uncertainty of whether combined therapy with a beta-blocker and calcium-channel antagonist provides additive or synergistic clinical benefits in most patients with stable angina pectoris. The comparative antianginal effect of atenolol 50 mg and atenolol 50 mg and slow release nifedipine (20 mg) twice a ...

journal_title：Cardiovascular drugs and therapy

authors： Meyer TE,Adnams C,Commerford P

更新日期：1993-12-01 00:00:00

abstract：:Specific antiarrhythmic therapy with class I and III drugs for atrial fibrillation (AF) conversion and prevention of its recurrence is frequently utilized in clinical practice. Besides being only moderate effective, the utilization of antiarrhythmic drugs may be associated with serious side effects. In the clinical se...

journal_title：Cardiovascular drugs and therapy

authors： Husser D,Stridh M,Sornmo L,Platonov P,Olsson SB,Bollmann A

更新日期：2004-09-01 00:00:00

abstract：OBJECTIVE:The natural history of pediatric patients with severely symptomatic neurocardiogenic syncope is poorly defined respect to the likelihood of remission or symptomatic recurrence along time. We undertook this study to investigate the likelihood of clinical relapse, and to assess the effect of prophylactic pharma...

journal_title：Cardiovascular drugs and therapy

authors： Biffi M,Boriani G,Bronzetti G,Frabetti L,Picchio FM,Branzi A

更新日期：2001-03-01 00:00:00

abstract：:The time course of myocardial ischemia was studied in canine myocardium by electron microscopy. Ischemia of the myocardium produces ultrastructural alterations of mitochondria, nuclei, contractile apparatus, and the SR- and T-tubular system that are accompanied by loss of glycogen and intracellular edema. These change...

journal_title：Cardiovascular drugs and therapy

authors： Schaper J,Schaper W

更新日期：1988-05-01 00:00:00

abstract：:The effects of administration of guava and papaya fruit (100 g/day), vegetables, and mustard oil (5 g/day) (group A); antioxidant vitamins C (50 mg/day) and E (30 mg/day), plus betacarotene (10 mg/day) (group B); a high-fat (5-10 g/day) (group C); or a low-fat (4-5 g/day) diet (group D) were compared over 24 diet week...

journal_title：Cardiovascular drugs and therapy

authors： Singh RB,Niaz AM,Ghosh S,Agarwal P,Ahmad S,Begum R,Onouchi Z,Kummerow FA

更新日期：1995-12-01 00:00:00

abstract：:In vitro and in vivo studies have demonstrated many similarities between the three calcium antagonists verapamil, nifedipine, and diltiazem in relation to protection of the myocardium during hypoxia. Important clinical differences exist between the three drugs when they are used during or after an acute myocardial inf...

journal_title：Cardiovascular drugs and therapy

authors： Hansen JF

更新日期：1991-08-01 00:00:00

abstract：:The following discourse addresses the pharmacologic profile of KT-362, its clinical potential as an anti-arrhythmic agent with associated hypotensive effects, as well as its additional related potential in myocardial ischemia and related sequellae, and the specific cellular actions that may be responsible for these po...

journal_title：Cardiovascular drugs and therapy

authors： Hester RK,Shibata S

更新日期：1990-10-01 00:00:00

abstract：:Ouabain, when applied to rings of the left circumflex coronary artery of the dog (which contains both alpha 1-adrenoceptors leading to contraction and beta 1-adrenoceptors leading to relaxation) caused an initial contraction which peaked within 15 minutes and a later secondary increase in tension which peaked within 6...

journal_title：Cardiovascular drugs and therapy

authors： Cooke JP,Shepherd JT,Vanhoutte PM

更新日期：1988-07-01 00:00:00

abstract：PURPOSE:Protein kinase C alpha (gene: PRKCA) is a key regulator of cardiac contractility. Two genetic variants have recently been discovered to regulate PRKCA expression in failing human heart tissue (rs9909004 [T → C] and rs9303504 [C → G]). The association of those variants with clinical outcomes in patients with hea...

journal_title：Cardiovascular drugs and therapy

authors： Luzum JA,Ting C,Peterson EL,Gui H,Shugg T,Williams LK,Li L,Sadee W,Wang D,Lanfear DE

更新日期：2019-12-01 00:00:00

abstract：:Calcium entry blockers exert several characteristic effects on renal function that contribute to their blood-pressure lowering capacity. They are able to dilate renal vasculature and, in certain circumstances, can increase the glomerular filtration rate, both effects being dependent on the preexisting vascular tone. C...

journal_title：Cardiovascular drugs and therapy

authors： Ruilope LM,Alcazar JM

更新日期：1990-08-01 00:00:00

abstract：:Forty-one chronically T. cruzi-infected male adult albino rats with normal resting ECG were submitted to the ajmaline test (1 mg/kg body weight injected into the dorsal vein of the penis). Twenty-one similar noninfected animals served as controls. Ajmaline induced the following ECG alterations in control rats: A decre...

journal_title：Cardiovascular drugs and therapy

authors： Bestetti RB,Soares EG,Sales-Neto VN,Oliveira JS

更新日期：1989-04-01 00:00:00

abstract：:High-density lipoprotein cholesterol (HDL-c) has long been referred to as 'good cholesterol' due to its apparent inverse relationship with future CVD risk. More recent research has questioned a causal role for HDL-c in this relationship, however, as both genetic studies and numerous large-scale randomised controlled t...

journal_title：Cardiovascular drugs and therapy

authors： Chiesa ST,Charakida M

更新日期：2019-04-01 00:00:00

abstract：:Colesevelam hydrochloride (colesevelam) is a novel, potent, bile acid-binding agent that has been shown to lower LDL cholesterol a mean of 19% at a dose of 3.8 g/d. We studied the pharmacokinetics of colesevelam coadministered with six drugs: digoxin and warfarin, agents with narrow therapeutic indices; sustained-rele...

journal_title：Cardiovascular drugs and therapy

authors： Donovan JM,Stypinski D,Stiles MR,Olson TA,Burke SK

更新日期：2000-12-01 00:00:00

abstract：:The calcium antagonist (CA) controversy has been fueled in part by disagreements among scientists and clinicians over the scientific documentation required for drugs used to treat lifelong conditions. From a public health perspective, there are three unanswered questions: (1) Does long-term use of CAs convey health be...

journal_title：Cardiovascular drugs and therapy

authors： Furberg CD,Psaty BM

更新日期：1996-09-01 00:00:00

abstract：PURPOSE:Treatment of atherosclerotic rabbits with intravenous methotrexate or etoposide carried in lipid nanoemulsions (LDE) markedly reduced the lesions in the aorta. Here, the combined treatment with LDE-methotrexate and LDE-etoposide was investigated aiming to increase the anti-atherosclerosis effect. METHODS:Thirt...

journal_title：Cardiovascular drugs and therapy

authors： Leite AC Jr,Solano TV,Tavares ER,Maranhão RC

更新日期：2015-02-01 00:00:00

abstract：PURPOSE:Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP). The present study is to quantitatively analyze and compare the contributions of multiple CYPs in the metabolism of rivaroxaban to provide new information for medication safety. METHODS:The metabolic stability ...

journal_title：Cardiovascular drugs and therapy

authors： Zhao T,Chen Y,Wang D,Wang L,Dong P,Zhao S,Wang C,Meng Q,Sun H,Liu K,Wu J

更新日期：2021-01-07 00:00:00

abstract：PURPOSE:Dofetilide is class III antiarrhythmic agent which prolongs cardiac action potential duration because of selective inhibition of I (Kr), the rapid component of the delayed rectifier K(+) current. Although clinical studies reported on proarrhythmic risk associated with dofetilide treatment, the contributing elec...

journal_title：Cardiovascular drugs and therapy

authors： Osadchii OE

更新日期：2012-12-01 00:00:00

abstract：:Reducing elevated levels of low-density-lipoprotein cholesterol (LDL-C) significantly reduces the incidence of coronary heart disease (CHD) events and mortality in hypercholesterolemic patients. CHD risk reduction is proportional to LDL-C reduction. Despite this knowledge, many physicians are not applying existing tre...

journal_title：Cardiovascular drugs and therapy

authors： McKenney JM

更新日期：2001-09-01 00:00:00

abstract：:To evaluate cordiodepressive risks of antiarrhythmic treatment with diprafenone, we monitored, in addition to conventional hemodynamic parameters, end-systolic pressure-volume relations to assess potential negative inotropic effects. Thirteen patients underwent hemodynamic analysis with and without the influence of di...

journal_title：Cardiovascular drugs and therapy

authors： Thormann J,Kramer W,Kremer P,Schlepper M

更新日期：1989-04-01 00:00:00

abstract：:Obesity is one of the most common lifestyle-related diseases. Being closely associated with insulin resistance, hypertension and dyslipidemia, it is also a component of metabolic syndrome and is involved in the development of atherosclerosis and cardiovascular and renal ailments. Obesity is also accompanied with a sta...

journal_title：Cardiovascular drugs and therapy

authors： Yan M,Mehta JL,Hu C

更新日期：2011-10-01 00:00:00

abstract：PURPOSE:Homocysteine (Hcy) is an independent risk factor for cardiovascular diseases that impairs endothelial function. We investigated whether the impaired endothelial function can be restored by the eNOS transcription enhancer AVE3085 in porcine coronary arteries. The effects of AVE3085 against Hcy on eNOS-NO functio...

journal_title：Cardiovascular drugs and therapy

authors： Yang Q,Xue HM,Underwood MJ,Yu CM

更新日期：2013-12-01 00:00:00

abstract：:The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below. ...

journal_title：Cardiovascular drugs and therapy

authors： Ahn R,Prasad V

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:Markers of thrombosis, inflammation, endothelial dysfunction and neurohumoral activation such as fibrinogen, D-dimer, C-reactive protein, von Willebrand factor, tumour necrosis factor-alpha and chromogranin-A are reported to be linked to the increase of cardiovascular risk for atherosclerosis progression and...

journal_title：Cardiovascular drugs and therapy

authors： Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators.

更新日期：2003-01-01 00:00:00

abstract：:To compare the antiischemic effects of intracoronary administration of a beta blocker, atenolol, and of a calcium antagonist, nifedipine, on the clinical and electrocardiographic signs of myocardial ischemia induced by balloon occlusion of the coronary artery, we studied 32 consecutive patients undergoing routine PTCA...

journal_title：Cardiovascular drugs and therapy

authors： Ghio S,De Servi S,Angoli L,Bramucci E,Eleuteri E,Raffaghello S,Specchia G

更新日期：1992-06-01 00:00:00

abstract：PURPOSE:Mechanical stretch is an arrhythmogenic factor found in situations of cardiac overload or dyssynchronic contraction. Ranolazine is an antianginal agent that inhibits the late Na (+) current and has been shown to exert a protective effect against arrhythmias. The present study aims to determine whether ranolazin...

journal_title：Cardiovascular drugs and therapy

authors： Chorro FJ,del Canto I,Brines L,Such-Miquel L,Calvo C,Soler C,Parra G,Zarzoso M,Trapero I,Tormos Á,Alberola A,Such L

更新日期：2015-06-01 00:00:00